# Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

> **NCT02747043** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 256 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** ABP 798
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT02747043
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-25
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02747043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02747043, "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02747043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*